Search | Clinical Trials Finder

Conditions: BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Solid Neoplasm
Interventions: Dabrafenib, Laboratory Biomarker Analysis, Onalespib, Pharmacological Study, Trametinib; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: BRAF V600 Mutation, Low-grade Glioma, Low Grade Glioma of Brain, Recurrent Low Grade Glioma
Interventions: Dabrafenib, Trametinib, Magnetic Resonance Imaging (MRI), Specimen Collection, Optional Lumbar puncture; Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 12 Months to 25 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 10
States / cities: Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 7 more

Conditions: Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
Interventions: Sunitinib (CLOSED TO ENROLLMENT), Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT), Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT), Olaparib (CLOSED TO ENROLLMENT), Nivolumab and Ipilimumab (CLOSED TO ENROLLMENT), Abemaciclib (CLOSED TO ENROLLMENT), Talazoparib (CLOSED TO ENROLLMENT), Atezolizumab and Talazoparib (CLOSED TO ENROLLMENT), Tucatinib plus Trastuzumab Subcutaneous (SC) (CLOSED TO ENROLLMENT), Futibatinib, Dabrafenib plus Trametinib, Fam-Trastuzumab Deruxtecan-Nxki (TDxD); Drug
Lead sponsor: American Society of Clinical Oncology; Other
Eligibility: 12 Years and older
Enrollment: 4,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 174
States / cities: Birmingham, Alabama • Phoenix, Arizona • Auburn, California + 137 more

Conditions: Cancer
Interventions: GSK1120212; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 3
States / cities: Detroit, Michigan • Nashville, Tennessee • San Antonio, Texas

Conditions: Cancer
Interventions: GSK1120212B (Standard DMSO content), GSK1120212B (Lower DMSO content); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 4
States / cities: Goodyear, Arizona • Scottsdale, Arizona • Sarasota, Florida + 1 more

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions: Trametinib Dimethyl Sulfoxide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Leukaemia, Myelocytic, Acute
Interventions: GSK1120212, Gemcitabine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Nashville, Tennessee • San Antonio, Texas

Conditions: Follicular Thyroid Cancer, Insular Thyroid Cancer, Papillary Thyroid Cancer, Recurrent Thyroid Cancer
Interventions: dabrafenib, trametinib; Drug
Lead sponsor: Bhavana Konda; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 5
States / cities: San Diego, California • Chicago, Illinois • Boston, Massachusetts + 2 more

Conditions: Colorectal Cancer, Colorectal Tumors, Colorectal Carcinoma, Colorectal Neoplasm
Interventions: Nivolumab, Trametinib, Ipilimumab, Regorafenib; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 16
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more

Conditions: Recurrent Melanoma, Stage IIB Melanoma (Locally Advanced), Stage IIC Melanoma (Locally Advanced), Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma (Limited, Resectable)
Interventions: dabrafenib, trametinib, laboratory biomarker analysis; Drug · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Non-small Cell Lung Cancer
Interventions: Rociletinib, Trametinib; Drug
Lead sponsor: Clovis Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: St Louis, Missouri • Charlotte, North Carolina • Nashville, Tennessee + 1 more

Conditions: Langerhans Cell Histiocytosis
Interventions: Trametinib; Drug
Lead sponsor: Cook Children's Health Care System; Other
Eligibility: 1 Year to 30 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2039
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Pancreatic Ductal Adenocarcinoma
Interventions: Trametinib, Ruxolitinib, Retifanlimab; Drug
Lead sponsor: Peter Hosein, MD; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood, Anaplastic Oligodendroglioma, Glioblastoma, Pilocytic Astrocytoma, Giant Cell Astrocytoma, Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Angiocentric Glioma, Chordoid Glioma of Third Ventricle, Gangliocytoma, Ganglioglioma, Anaplastic Ganglioglioma, Dysplastic Gangliocytoma of Cerebrellum, Desmoplastic Infantile Astrocytoma and Ganglioglioma, Papillary Glioneuronal Tumor, Rosette-forming Glioneuronal Tumor, Central Neurocytoma, Extraventricular Neurocytoma, Cerebellar Liponeurocytoma, Neurofibromatosis Type 1
Interventions: dabrafenib, trametinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 1 Year to 99 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 11
States / cities: Phoenix, Arizona • Washington D.C., District of Columbia • Miami, Florida + 8 more

Conditions: BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions: Dabrafenib, Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Trametinib; Drug · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Unresectable Pancreatic Carcinoma
Interventions: Hydroxychloroquine, Trametinib; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: San Francisco, California • Salt Lake City, Utah

Conditions: Advanced Malignant Solid Neoplasm
Interventions: Adavosertib, Carboplatin, Everolimus, Temozolomide, Trametinib, Veliparib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 8
States / cities: Aurora, Colorado • Atlanta, Georgia • Lexington, Kentucky + 5 more

Conditions: Lung Cancer, Non-Small Cell
Interventions: GSK1120212, docetaxel; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 25
States / cities: Scottsdale, Arizona • Orange, California • Aurora, Colorado + 20 more

Conditions: Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions: Akt Inhibitor GSK2141795, Laboratory Biomarker Analysis, Trametinib; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 8
States / cities: Washington D.C., District of Columbia • Tampa, Florida • Buffalo, New York + 4 more

Conditions: Cancer
Interventions: GSK1120212, GSK2110183; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Dallas, Texas • San Antonio, Texas

Conditions: Breast Cancer
Interventions: GSK1120212; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: BRAFV600E Melanoma Patients
Interventions: Dabrafenib, Gamma Knife Radiosurgery, Trametinib; Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Recurrent World Health Organization (WHO) Grade II Glioma, Low-grade Glioma, High-Grade Glioma (HGG)
Interventions: Everolimus, Trametinib; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 1 Year to 25 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 17
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more

Conditions: Bile Duct Cancer, Biliary Cancer, Biliary Tract Neoplasms, Cholangiocarcinoma
Interventions: Trametinib, Hydroxychloroquine; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

GSK1120212 Food-effect Study

A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies

Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)

Combination Study of GSK1120212 With Gemcitabine in Subjects With Solid Tumors

Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer

An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread

Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery

Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer

Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib

Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma

Pediatric Long-Term Follow-up and Rollover Study

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer

MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations

An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer

A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers

Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212

Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).